Yazar "Demirci, Nebi Serkan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.
    (Amer Soc Clinical Oncology, 2016) Ozdemir, Nuriye; Demirci, Nebi Serkan; Yuksel, Sinemis; Erdem, Gokmen Umut; Odabas, Hatice; Boruban, Melih Cem; Hacibekiroglu, Ilhan
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
    (Ios Press, 2018) Bozkaya, Yakup; Ozdemir, Nuriye Yildirim; Sezer, Sevilay; Kostek, Osman; Demirci, Nebi Serkan; Yazici, Ozan; Erdem, Gokmen Umut
    BACKGROUND: The potential prognostic value of survivin is variably reported depending on the gastric cancer. OBJECTIVE: Evaluation of the prognostic and predictive significance of serum survivin and its relation with survival and treatment response rates in patients with locally advanced gastric cancer (LAGC). METHODS: Serum samples were prospectively collected from 50 patients with newly diagnosed LAGC. Serum samples of 32 healthy subjects were also collected as control groups for survivin levels. Serum survivin levels were evaluated at baseline and after three cycles of neoadjuvant chemotherapy in LAGC patients. RESULTS: Median survivin level was 147 IU/L (range = 4.4-4936) at baseline and was 27 IU/L (range = 4.2-4737) after neoadjuvant chemotherapy. The difference between survivin levels of the control group (26 IU/L, range = 3.8-1430) and pretreatment patient group was statistically significant (p < 0.001). Clinical response to mDCF regimen was classified as progressive (progressive disease) and non-progressive groups (partial response + stable disease). Baseline survivin levels were similar between patients in progressive and non-progressive groups (p = 0.55). Survivin levels were significantly reduced after chemotherapy in non-progressive group (p < 0.001). In contrast, serum survivin levels increased in a stepwise fashion from baseline to post-chemotherapy in patients with progressive disease (p = 0.06). Patients were divided into low and high survivin groups according to baseline median survivin levels. Median DFS was 12.4 and 14.6 months for low and high groups, respectively (p = 0.18). Moreover, median OS was 14.4 and 24.9 months for low and high group, respectively (p = 0.14). CONCLUSION: It can be suggested that serum survivin can be used as a predictor of response to chemotherapy-but not survival-in LAGC patients receiving neoadjuvant mDCF chemotherapy. However, large multicenter prospective studies are required to confirm these results.
  • Küçük Resim Yok
    Öğe
    Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients
    (Taylor & Francis Ltd, 2019) Bozkaya, Yakup; Erdem, Gokmen Umut; Demirci, Nebi Serkan; Yazic, Ozan; Ozdemir, Nuriye Yildirim; Kostek, Osman; Zengin, Nurullah
    Aim: The aim of this study was to evaluate the prognostic importance of the albumin to globulin ratio (AGR) in terms of overall survival (OS) and progression free survival (PFS) in metastatic gastric cancer patients. Methods: The patients diagnosed with metastatic gastric cancer between 2009 and April 2016 at the hospital have been studied retrospectively. The clinicopathological characteristics, laboratory, and treatment parameters have been assessed. AGR value has been calculated using the following formula (AGR = serum albumin/total protein - serum albumin). Results: In total, 251 patients were included in the study population. The median value of AGR was 1.206 (range = 0.460-3.130), and the cut-off value was set as 1.20. Based on the cut-off value, 126 patients were categorized in the low AGR group, while the remaining 125 patients were categorized in the high AGR group. ECOG (Eastern Cooperative Oncology Group) performance scores, CEA levels, CA19-9 levels, hemoglobin levels, lactate dehydrogenase levels, and liver metastasis ratios varied significantly between the low and high AGR groups (p < .05). The Kaplan-Meier curve has shown that, compared to the low AGR group, the high AGR group has better OS (12.2 vs 9.3 months, p = .002) and better PFS (8.0 vs 5.7 months, p < .001) rates. The univariate and multivariate analyses also proved that low AGR is an independent bad risk factor in metastatic gastric cancer patients, both in terms of OS (p = .019, Hazard Ratio (HR) = 1.380, 95% Confidence Interval (CI) = 1.055-1.805) and PFS (p = .002, HR = 1.514, 95% CI = 1.164-1.968). Conclusion: In metastatic gastric cancer patients, AGR is an independent prognostic factor for OS and PFS. Thus, in this patient group, the low cost albumin and globulin which can be measured with routine clinical practice may be used as an appropriate prognostic tool.